616.234.5000

Publications

Steensma Laboratory

Selected Publications

Peacock JD, Pridgeon MG, Tovar EA, Essenburg CJ, Bowman M, Madaj Z, Koeman J, Boguslawski EA, Grit J, Dodd RD, Khachaturov V, Cardona DM, Chen M, Kirsch DG, Maina F, Dono R, Winn ME, Graveel CR, Steensma MR. 2018. Genomic status of MET potentiates sensitivity to MET and MEK inhibition in NF1-related malignant peripheral nerve sheath tumors. Cancer Res 78(13):3672–3687.

Pridgeon MG, Grohar PJ, Steensma MR, Williams BO. 2017. Wnt signaling in Ewing sarcoma, osteosarcoma, and malignant peripheral nerve sheath tumors. Curr Osteo Rep 15(4):239–246.

Linklater ES, Tovar EA, Essenburg CJ, Turner L, Madaj Z, Winn ME, Melnik MK, Korkaya H, Maroun CR, Christensen JG, Steensma MR, Boerner JL, Graveel CR. 2016. Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers. Oncotarget 7(43):69903.

Steensma MR, Jebson P. 2016. Primary bone sarcomas of the upper extremity. In Tumors of the Hand and Upper Extremity. Edward A. Athanasian, Peter J. Jebson, Sanjeev Kakar, Peter M. Murray, eds. Chicago, IL: American Society for Surgery of the Hand, p. 6.

Lane BR, Bissonnette J, Waldherr T, Ritz-Holland D, Chesla D, Cottingham SL, Alberta S, Liu C, Thompson AB, Graveel C, MacKeigan JP, Noyes SL, Smith J, Lakhani N, Steensma MR. 2015. Development of a Center for Personalized Cancer Care at a regional cancer center: Feasibility trial of an institutional tumor sequencing advisory boardJ Mol Diagn 17(6):695–704.

Foley JM, Scholten DJ 2nd, Monks N, Cherba D, Monsma D, Davidson P, Dylewski D, Dykema K, Winn M, Steensma MR. 2015. Anoikis-resistant subpopulations of human osteosarcoma display significant chemoresistance and are sensitive to targeted epigenetic therapies predicted by expression profiling. J Trans Med 3:110.

Peacock JD, Dykema KJ, Toriello HV, Mooney MR, Scholten DJ 2nd, Winn ME, Borgman A, Duesbery NS, Hiemenga JA, Liu C, Campbell S, Nickoloff BP, Williams BO, Steensma MR. 2015. Oculoectodermal syndrome is a mosaic RASopathy associated with KRAS alterations. Am J Med Genet 167(7):1429–1435.    

Pelle DW, Ringler JW, Peacock JD, Kampfschulte K, Scholten DJ 2nd, Davis MD, Mitchell DS, Steensma MR. 2014. Targeting receptor-activator nuclear kappa beta ligand in aneurysmal bone cysts: verification of target and therapeutic response. Transl Res 164(2):139–148.

Pelle DW, Peacock JD, Schmidt CL, Kampfschulte K, Scholten DJ 2nd, Russo SS, Easton KJ, Steensma MR. 2014. Genetic and functional studies of the intervertebral disc: A novel murine intervertebral disc model. PLoS One 9(12)e112454.  

Scholten DJ 2nd, Timmer CM, Peacock JD, Pelle DW, Williams BO, Steensma MR. 2014. Down regulation of Wnt signaling mitigates hypoxia-induced chemoresistance in human osteosarcoma cells. PLoS One 9(10):e111431.  

Puhaindran M, Schlumbohm S, Hamilton K, Rich M, Mitchell D, Steensma MR. 2014. Radiation-induced osteosarcoma of the handJ Hand Surg Am 39(6):1151–1154.  

Pelle DW, Ringler JW, Peacock JD, Kampfschulte K, Scholten II DJ, Davis MD, Mitchell DS, Steensma MR. 2014. Targeting receptor-activator nuclear kappa beta ligand in aneurysmal bone cysts: verification of target and therapeutic response. Transl Res 164(2):139–148.  

Peacock JD, Cherba D, Kampfschulte K, Smith MK, Monks NR, Webb CP, Steensma MR. 2013. Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors. J Transl Med 11(1):213.  

Steensma MR, Tyler WK, Shaber AG, Goldring SR, Ross FP, Williams BO, Healey JH, Purdue PE. 2013. Targeting the giant cell tumor stromal cell: functional characterization and a novel therapeutic strategy. PLoS One 8(7): e69101.  

Monks NR, Cherba DM, Kamerling SG, Simpson H, Rusk AW, Carter D, Eugster E, Mooney M, Sigler R, Steensma MR, Grabinski T, Marotti KR, Webb CP. 2013. A multi-site feasibility study for personalized medicine in canines with osteosarcoma. J Transl Med 11:158.   

Valkenburg KC, Steensma MR, Williams BO, Zhong Z. 2013. Skeletal metastasis: treatments, mouse models, and the Wnt signaling. Chin J Cancer 32(7):380–396.   

Steensma MR, Healey JH. 2013. Trends in the surgical treatment of pathologic proximal femur fractures among Musculoskeletal Tumor Society members. Clin Orthop and Relat Res 471(6): 2000–2006.   

Steensma MR, Morris C. 2013. Ewing’s sarcoma. In Orthopaedic Knowledge Update: Musculoskeletal Tumors 3, J. Sybil Biermann, ed. Rosemont, IL: American Academy of Orthopaedic Surgeons.

Steensma MR, Boland PJ, Morris CD, Athanasian E, Healey JH. 2012. Endoprosthetic treatment is more durable for pathologic proximal femur fractures. Clin Orthop Relat Res 470(3):920–926.  

Zhong Z, Williams BO, Steensma MR. 2012. Commentary on “The activation of Beta-catenin by Gs contributes to the etiology of phenotypes seen in fibrous dysplasia and McCune–Albright syndrome”. IBMS BoneKEy 9.   

Puhaindran M, Farooki A, Steensma MR, Hameed M, Healey JH, Boland PJ. 2011. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates. J Bone Joint Surg Am 93(13):1235–1242.   

Puhaindran M, Steensma MR, Athanasian E. 2010. Partial hand preservation for large soft tissue sarcomas of the hand. J Hand Surg Am 35(2):291–295.   

Steensma MR, Jabara M, Anderson JG, Bohay DR. 2006. Flexor hallucis longus tendon transfer for hallux claw toe deformity and vertical instability of the metatarsophalangeal joint. Foot Ankle Int 27(9):689–692.   

Steensma MR, Anderson JG, Bohay DR. 2005. Update on diseases and treatment of the peroneal tendon including peroneal tendon tear, subluxating peroneal tendon, and tendinosis. Curr Opin Ortho 2:60–65.